731 Costs of care for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): a real-world claims analysis

731 Costs of care for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): a real-world claims analysis

Bibliographic Details
Main Authors:	Jonathan Kish, Dhruv Chopra, Djibril Liassou, Solomon Lubinga, John Hartman, Bruce Feinberg
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

La historicidad de Marcos 7,31
by: Alberto González García
Published: (2017-10-01)

The promise and perils of Unit 731 data to advance COVID-19 research
by: Xiaoshan Li, et al.
Published: (2021-05-01)

Expression and purification 13C- and 15N-labeled β-amyloid peptide and β-amyloid precursor protein 672-731(APP 672-731) for NMR structural analysis and study
by: Han-Chen Chang, et al.
Published: (2006)

Factors associated with intensive care admission in patients with lung cancer: a population-based observational study of 26, 731 patients
by: Kathryn Puxty, et al.
Published: (2020-02-01)

Validation of a Case-Finding Algorithm for Identifying Patients with Non-small Cell Lung Cancer (NSCLC) in Administrative Claims Databases
by: Ralph M. Turner, et al.
Published: (2017-11-01)

Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset
by: David Waterhouse, et al.
Published: (2021-08-01)

Lung microbiome alterations in NSCLC patients
by: Leliang Zheng, et al.
Published: (2021-06-01)

Using spectral characteristics to interpret auroral imaging in the 731.9 nm O<sup>+</sup> line
by: H. Dahlgren, et al.
Published: (2008-07-01)

POS-731 PARVOVIRUS DISEASE POST RENAL TRANSPLANT PRESENTING AS REFRACTORY ANEMIA-SINGLE CENTRE EXPERIENCE
by: U. Hegde, et al.
Published: (2021-04-01)

A Model Following Based Real-Time Prediction and Monitoring of TFE-731 Turbofan Engine Compressors
by: Shih-Huai Chen, et al.
Published: (2019-01-01)

Real-world research of advanced NSCLC immunotherapy based on iRECIST criteria
by: CHEN Mingjing, et al.
Published: (2020-03-01)

Immunotherapeutic Advances for NSCLC
by: Massafra M, et al.
Published: (2021-10-01)

The Study and Improvement of Interstage Temperature Anomaly Using the Analytical Hierarchical Process (AHP) for TFE731 Turbine Engine
by: Shao-ChunLiu, et al.
Published: (2012)

COMENSALIDADE E ASCESE: CONFLITOS DE PROJETOS MESSIÂNICOS A PARTIR DE LC 7,31-35
by: Orti, Luiz Vitório
Published: (2016)

„Przemija bowiem postać tego świata” (1 Kor 7,31). Dziewictwo i celibat znakiem królestwa
by: Roman Bogacz
Published: (2013-12-01)

A 73.1dB SNDR Digitally Assisted Subsampler for RF Power Amplifier Linearization Systems
by: Chung, SungWon, et al.
Published: (2011)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
by: Joshua E. Reuss, MD, et al.
Published: (2021-10-01)

ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PATIENTS’ ILLNESS PERCEPTIONS AT DIAGNOSIS
by: Stephen B. Lo, et al.
Published: (2019-06-01)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
by: Irene Moya-Horno, et al.
Published: (2018-01-01)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
by: Enriqueta Felip, et al.
Published: (2008-06-01)

http://www.sportmont.ucg.ac.me/clanci/SportMont_Maj_2007_Mijajlovic_725-731.pdf
by: Miodrag Drapšin, et al.
Published: (2007-05-01)

Effatha: aproximación exegética al relato de curación del tartamudo sordo en Mc 7,31-37
by: Juan Alberto Casas Ramírez
Published: (2016-07-01)

Osimertinib in NSCLC: Real-World Data From New Zealand
by: Yeojeong Jane So, MbChB, FRACP, et al.
Published: (2020-06-01)

Treatments of Advanced Non‑Small Cell Lung Cancer (NSCLC) in an Italian Center: Drug Utilization and the Treatment Costs of Innovative Drugs
by: Francovito Piantedosi, et al.
Published: (2019-03-01)

Evaluation of Efficacy of Gefitinib on Advanced non-small-cell Lung Cancer (NSCLC) Resisted to Chemotherapy
by: Jiangjiang TU, et al.
Published: (2008-04-01)

Prognostic Factors in Non-Small Cell Lung Cancer (NSCLC)
by: Holgersson, Georg
Published: (2017)

Casual blood glucose and subsequent cardiovascular disease and all-cause mortality among 159 731 participants in Cohort of Norway (CONOR)
by: Hilde Kristin Refvik Riise
Published: (2021-08-01)

Soreness during non-music activities is associated with playing-related musculoskeletal problems: an observational study of 731 child and adolescent instrumentalists
by: Sonia Ranelli, et al.
Published: (2014-06-01)

Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.
by: Paul Germonpré, et al.
Published: (2019-01-01)

Claiming and Making Muslim Worlds Religion and Society in the Context of the Global
Published: (2021)

Advances in Oligonucleotide Aptamers for NSCLC Targeting
by: Deborah Rotoli, et al.
Published: (2020-08-01)

Recent Advances in Immunotherapy in Metastatic NSCLC.
by: Pranshu Bansal, et al.
Published: (2016-11-01)

Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience
by: Lavinia Monaco, et al.
Published: (2021-04-01)

Imaginary Worlds: The Status of Simulation Modeling in Claims for Cost-Effectiveness In Diabetes Mellitus
by: Paul C Langley, et al.
Published: (2016-07-01)

Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors
by: Paul C Langley, Dr
Published: (2017-05-01)

Cost-Effectiveness and Formulary Evaluation: Imaginary Worlds and Entresto Claims in Heart Failure
by: Paul C Langley
Published: (2016-09-01)

Corrigendum: Treatments of Advanced Non‑Small Cell Lung Cancer (NSCLC) in an Italian Center: Drug Utilization and the Treatment Costs of Innovative Drugs
by: [No authors listed]
Published: (2019-06-01)

Claiming Space : Locations and Orientations in World Literatures
Published: (2021)

Phase II study of Gemcitabine and Cisplatin Regimen in Advanced Non-Small Cell Lung Cancer (NSCLC).
by: M Hoseinzadeh Mollayosefy, et al.
Published: (2005-06-01)

Phase II study of Gemcitabine and Cisplatin Regimen in Advanced Non-Small Cell Lung Cancer (NSCLC).
by: Hoseinzadeh Mollayosefy M, et al.
Published: (2005-07-01)

Cannot write session to /tmp/vufind_sessions/sess_b4n73vmmsc83lis8omrb76r0oh